Buscar
Harrow Inc
HROWAñadir a la lista de seguimiento
41.500USD
-1.180-2.76%
Cierre 06/25, 16:00（ET）Cotizaciones retrasadas 15 min
1.55BCap. mercado
PérdidaP/E TTM
Más Datos de Harrow Inc Compañía
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Información de Harrow Inc
Símbolo de cotizaciónHROW
Nombre de la empresaHarrow Inc
Fecha de salida a bolsaFeb 08, 2013
Director ejecutivoMullery (Frank)
Número de empleados382
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 08
Dirección1A Burton Hills Blvd
CiudadNASHVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal37215
Teléfono16157334731
Sitio Webhttps://www.harrow.com/
Símbolo de cotizaciónHROW
Fecha de salida a bolsaFeb 08, 2013
Director ejecutivoMullery (Frank)
Ejecutivos de Harrow Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Randall E. Pollard, CPA
Mr. Randall E. Pollard, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Mr. Frank Mullery
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Chief Executive Officer of ImprimisRx
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.00M
+0.33%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
President, Chief Financial Officer, Company Secretary
President, Chief Financial Officer, Company Secretary
814.68K
+0.43%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
19.80K
+5.05%
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
19.80K
+5.05%
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Harrow Inc?
Los cinco principales accionistas de Harrow Inc son: Mr. Mark L. Baum, J.D.
¿Cuántas instituciones poseen acciones de Harrow Inc (HROW)?
A fecha de 2026Q1, 418 instituciones poseen acciones de Harrow Inc, con un valor de mercado combinado de aproximadamente 24.67M, lo que representa el 66.17% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 347374.00.
